<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16</volume><submitter>Zhu C</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>To assess the impact of Sancai Lianmei (SCLM) granules on diabetic ischemic stroke (IS) model rats, as well as oxygen and glucose deprivation (OGD)-induced PC12 neurons and lipopolysaccharide (LPS)-induced BV2 microglia, and to investigate the associated mechanisms.&lt;h4>Methods&lt;/h4>Initially, a diabetic IS model was established in rats through the intraperitoneal administration of niacinamide (NAA) in conjunction with streptozotocin (STZ), supplemented by thread embolization. The model rats were subsequently observed behaviorally, pathologically, and molecularly. Ultimately, the specific mechanism underlying SCLM was elucidated and validated through &lt;i>in vitro&lt;/i> experiments.&lt;h4>Results&lt;/h4>SCLM improved neurological deficits and reduced infarct size in diabetic ischemic s</pubmed_abstract><journal>Frontiers in endocrinology</journal><pagination>1666597</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12420211</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Sancai Lianmei granules ameliorate neuron injury in diabetic ischemic stroke rats by inhibiting oxidative stress and inflammation.</pubmed_title><pmcid>PMC12420211</pmcid><pubmed_authors>Chen Q</pubmed_authors><pubmed_authors>Li Z</pubmed_authors><pubmed_authors>Han X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Zhu C</pubmed_authors><pubmed_authors>Chen D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Sancai Lianmei granules ameliorate neuron injury in diabetic ischemic stroke rats by inhibiting oxidative stress and inflammation.</name><description>&lt;h4>Purpose&lt;/h4>To assess the impact of Sancai Lianmei (SCLM) granules on diabetic ischemic stroke (IS) model rats, as well as oxygen and glucose deprivation (OGD)-induced PC12 neurons and lipopolysaccharide (LPS)-induced BV2 microglia, and to investigate the associated mechanisms.&lt;h4>Methods&lt;/h4>Initially, a diabetic IS model was established in rats through the intraperitoneal administration of niacinamide (NAA) in conjunction with streptozotocin (STZ), supplemented by thread embolization. The model rats were subsequently observed behaviorally, pathologically, and molecularly. Ultimately, the specific mechanism underlying SCLM was elucidated and validated through &lt;i>in vitro&lt;/i> experiments.&lt;h4>Results&lt;/h4>SCLM improved neurological deficits and reduced infarct size in diabetic ischemic s</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025</publication><modification>2026-06-02T20:35:54.352Z</modification><creation>2026-04-20T03:10:00.647Z</creation></dates><accession>S-EPMC12420211</accession><cross_references><pubmed>40937410</pubmed><doi>10.3389/fendo.2025.1666597</doi></cross_references></HashMap>